7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Shareholder votes
Reports First Quarter 2025 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Other Events
Amended material disclosure
Reports Positive Top Line Results from Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients with Ulcerative Colitis
Phase 3 VERIFY Study Topline Results March 3, 2025
Q2
Q1
FY 2023
Q3
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence